Basic and clinical evaluation of cefuroxime (CXM) for otorhinolaryngological infections.

概要

論文の詳細を見る
1. The sensitivity to CXM of bacteria cultured from otorhinolaryngological infections was examined. The MICs of CXM were ≤0.05μg/ml for (S. pneumoniae and S. pyogenes, and 0.39-0.78μg/ml for) H. influenzae.2. Tissue concentrations of CXM were also examined. In the palatine tonsils the concentration of CXM after iv doses of 750mg and 1.5g were 12.52-46.88μg/g at 15 minutes, 17.2μg/g at 60 minutes and 17.98μg/g at 120 minutes. In the maxillary sinus mucosa the concentration of CXM after an iv dose of 1.5g was 22.74μg/g at 60 minutes and 14.08μg/g at 180 minutes.3. Fifty-one patients with otorhinolaryngological infections were treated with CXM, 1.5g-3.0g daily by bolus iv injection or iv drip infusion in two divided doses. Clinical improvement was noted in 90% (23/24) in tonsillitis, 100% (6/6) in peritonsillar abscess, and 100% (9/9) in pharyngitis. The overall efficacy was 94% (48/51).4. Bacteriological eradication was noted in 90% (18/20) for S. pyogenes, 100% (5/5) for S. pneumoniae and 100% (5/5) for H. influenzae.5. No side effects or abnormal laboratory findings were found with the administration of CXM.
耳鼻咽喉科臨床学会の論文